Compare XRX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | AKBA |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 343.4M |
| IPO Year | 2019 | 2014 |
| Metric | XRX | AKBA |
|---|---|---|
| Price | $3.26 | $0.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $4.67 |
| AVG Volume (30 Days) | ★ 3.7M | 3.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | 23.26 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $0.82 |
| 52 Week High | $4.42 | $3.44 |
| Indicator | XRX | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 29.48 |
| Support Level | $2.40 | $0.85 |
| Resistance Level | $3.74 | $1.54 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 55.91 | 19.68 |
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.